Posting of Circular and Notice of General Meeting

Futura Medical PLC

04 September 2026

 

4 September 2026

Futura Medical plc

("Futura", "the Group" or the "Company")

Posting of Circular and Notice of General Meeting

Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon^® and that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that further to the announcement on 3 September 2026 relating to the Fundraise, it has despatched the Circular and Notice of General Meeting to Shareholders.

The Circular and Notice of General Meeting is available on the Company's website: https://futuramedical.com/investor-centre/corporate-documentation/

The Directors confirm they are to hold a General Meeting of the Company at the to be held at the offices of Panmure Liberum at Ropemaker Place, Level 12, 25 Ropemaker Street, London, England, EC2Y 9LY at 10:00 a.m. on 23 September 2026.

The results of voting on all resolutions at the General Meeting will be announced via RNS, and the full results of the voting will be published on the Company's website after the conclusion of the General Meeting. 

Contacts:

Futura Medical plc	Alex Duggan Chief Executive Officer Angela Hildreth Finance Director and COO	[e-mail] [phone] www.futuramedical.com
Panmure Liberum Nominated Adviser and Broker	Emma Earl, Will Goode, Mark Rogers (Corporate Finance)	[phone]
Turner Pope Investments (TPI) Ltd - Broker	Guy McDougall, Andrew Thacker	[phone]
Alma Strategic Communications	Rebecca Sanders-Hewett, Sam Modlin, Sarah Peters	[phone] [e-mail]

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative, consumer-focused, sexual health products, including lead product Eroxon^® and development projects WSD4000 and Eroxon^® Intense. Our core strength lies in our research, development, regulatory and business development expertise in developing innovative, clinically proven, insight-led and effective products to support our customers in the growing sexual health market.

Sexual health issues are prevalent globally in both men and women. Erectile Dysfunction ("ED") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. 60% of women experience at least one symptom of impaired sexual response or function in a twelve month period, with only one in four women seeking professional help and remaining chronically underserved.

Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of ED. The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection fast, addresses significant unmet needs in the ED market. Multiple license or distribution partnerships are in place for Eroxon®, across major consumer markets.

WSD4000 is a project name for our development female sexual health portfolio, starting with the creation of a range of topical gels under our unique platform technology, specifically designed to treat symptoms of sexual dysfunction in women. There is currently no known regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, impaired arousal, lubrication, ability to orgasm and overall sexual satisfaction.

 

END